MedTrace Logo

Additive Effects of 4-7-8 Breathing Technique With Standard Management on Dyspnea, Pulmonary Function and Quality of Life in Patients With COPD.

NCT06966063 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-15

No results posted yet for this study

Summary

A heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema)-- cause persistent, often progressive, airflow obstruction.

Breathing exercises help to manage dyspnea and reduced pulmonary function often seen in COPD patients. To handle respiratory complications COPD patients are advised to practice breathing techniques in conjunction with their prescribed medications.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Dyspnea

Interventions

PROCEDURE

4-7-8 breathing along with standard management.

For 4-7-8 breathing, Patient is asked sit in comfortable position. Patient is asked place the tip of your tongue up against the back of your front teeth. Keep it there through the entire breathing process. Instruct the patient to breathe in silently through your nose to the count of four (4sec) and Hold your breath to the count of seven (7sec). Exhale through your mouth to the count of eight (8sec), making an audible "whoosh" sound. That completes one full breath. Repeat the cycle another three time, and gradually in increase the cycle four time. Total 4 weeks protocol. Two sessions per week will be supervised by physiotherapist and 5 days at home. Week 01 and 02 Frequenc: 01 session/day Intensity: Start with comfortable duration. Time: 10 minutes Week 03 and 04 Frequecy: 02 sessions/day Intensity: 4 sec inhale, 7 sec hold and 8 sec exhale Time: 15 minutes

PROCEDURE

Control Group

Patients will recieve medication as prescribed by pulmonologist through stepwise approach according to symptoms and severity. Total 4 weeks protocol. Before and after 4 weeks pre and post interventional values will be taken. Week 01 and 02 Patients will receive medications prescribed by pulmonologist. Week 03 and 04 Patients will receive medications prescribed by pulmonologist.

Sponsors & Collaborators

  • Foundation University Islamabad

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-15
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06966063 on ClinicalTrials.gov